Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study

BACKGROUND: We aimed to quantify patients’ benefit-risk preferences for attributes associated with human epidermal growth factor receptor 2 (HER2)-targeted breast cancer treatments and estimate minimum acceptable benefits (MABs), denominated in additional months of progression-free survival (PFS), f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansfield, Carol, Botha, Willings, Vondeling, Gerard T., Klein, Kathleen, Wang, Kongming, Singh, Jasmeet, Hackshaw, Michelle D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454390/
https://www.ncbi.nlm.nih.gov/pubmed/36074320
http://dx.doi.org/10.1007/s12282-022-01394-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454390/
https://www.ncbi.nlm.nih.gov/pubmed/36074320
http://dx.doi.org/10.1007/s12282-022-01394-6

Ejemplares similares